JLPC(SH:600513)2023-03-02 16:00Financial Performance - The company's operating revenue for 2022 was approximately CNY 1.96 billion, representing an increase of 18.80% compared to CNY 1.65 billion in 2021[21]. - The net profit attributable to shareholders for 2022 was approximately CNY 141.37 million, an increase of 18.96% from CNY 118.84 million in 2021[21]. - The basic earnings per share for 2022 was CNY 0.49, up 19.51% from CNY 0.41 in 2021[20]. - The net cash flow from operating activities for 2022 was approximately CNY 127.59 million, a decrease of 7.77% compared to CNY 138.34 million in 2021[21]. - The total assets at the end of 2022 were approximately CNY 2.71 billion, reflecting a 15.29% increase from CNY 2.35 billion at the end of 2021[21]. - The net assets attributable to shareholders at the end of 2022 were approximately CNY 1.27 billion, an increase of 9.37% from CNY 1.16 billion at the end of 2021[21]. - The company’s operating costs increased by 7.8% year-on-year to 16,984.6 billion RMB in 2022[36]. - The company reported a net cash flow from operating activities of RMB 127.59 million, a decrease of 7.77% compared to the previous year[66]. - The company achieved a revenue of 1.955 billion RMB in 2022, representing an 18.80% year-on-year growth[51]. - The net profit attributable to the parent company was 141 million RMB, with an 18.96% increase compared to the previous year[51]. Research and Development - The company invested 107.18 million RMB in R&D, accounting for 5.48% of operating revenue, which is a 26.08% increase year-on-year[27]. - Research and development expenses rose by 39.06% to 92.44 million RMB, reflecting increased investment in R&D projects[52]. - The company has a strong R&D team, including academicians and high-quality talents, focusing on innovation and technology development[46]. - The company has successfully developed and launched 2 national class I new drugs, 6 former class II new drugs, and 2 former class III new drugs, with a total of 84 domestic patents, including 27 invention patents[46]. - The company completed Phase I clinical trials for the innovative diabetes drug LH-1801 and is currently conducting Phase I trials for the leukemia drug LH-1802[84]. - The company has made significant progress in the development of various innovative drugs, with multiple projects at different stages of clinical trials and evaluations[84]. - The company has established partnerships with several research institutions to enhance its R&D capabilities and innovation[82]. - The company achieved a significant increase in R&D investment for anti-tumor innovative drugs, with an increase of 505.51% compared to the previous year[93]. Market and Sales - The sales volume of Aipuleite tablets reached 86.01 million pieces, a year-on-year increase of 17.80%[29]. - Domestic sales revenue reached 1.901 billion RMB, up 20.23% year-on-year, while export sales dropped by 28.65%[56]. - The company’s sales network for formulation products covers the entire country, with sales offices established in key provinces and cities[39]. - The company’s main product, Aipulete Tablets, is recognized as a national class I new drug for treating benign prostatic hyperplasia[47]. - The company’s product, Dexamethasone Injection, was the first in the country to pass the consistency evaluation, and Azithromycin Tablets also passed this evaluation[83]. - The company won bids for key products, including Ebastine Tablets at 0.5657 CNY per tablet and Aminomethylbenzoic Acid Injection at 3.26 CNY per 10ml[77][78]. - The company is focused on expanding its market presence and developing new growth points through proactive marketing strategies[113]. Corporate Governance - The company has a structured board governance with independent directors and specialized committees to ensure compliance with legal and regulatory requirements[116]. - The company has established effective communication channels with shareholders, ensuring their rights and participation in major decisions[115]. - The company has a performance evaluation and incentive mechanism for senior management, aligning their compensation with company performance[117]. - The company ensures the independence of its operations and governance structure, with no interference from controlling shareholders[120]. - The company has committed to maintaining independent business operations, with adequate assets, personnel, and capabilities[120]. - The company has a clear plan for future governance and operational independence, ensuring compliance with legal and regulatory requirements[120]. Environmental Responsibility - The company has implemented various pollution control facilities, including organic waste gas treatment systems operational since 2013 and 2017[167]. - The company reported no exceedance of emission standards for major pollutants during the monitoring period[165]. - The company has established an environmental risk prevention system and conducted daily environmental hazard inspections, along with training and emergency drills[169]. - The company has committed to enhancing environmental awareness and compliance with regulations following the administrative penalties received[172]. - The company has engaged in various environmental monitoring and waste disposal practices, ensuring adherence to legal standards and promoting sustainable operations[173]. - The company has established a distributed photovoltaic project with a capacity of 1.526 MW to reduce carbon emissions, achieving a reduction of 651 tons of CO2 equivalent[179]. - The company has invested a total of 671,600 CNY in social responsibility projects, focusing on product quality, safety production, and environmental protection[180]. Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12%[128]. - New product launches are expected to contribute an additional 300 million yuan in revenue, with a focus on innovative drug formulations[127]. - The company is investing in market expansion, targeting a 25% increase in market share in the next two years[126]. - The company plans to accelerate talent acquisition and strengthen its R&D capabilities to drive innovation and enhance competitiveness in 2023[104]. - The company aims to enhance operational efficiency, targeting a reduction in production costs by 5% over the next year[126]. - The company is committed to enhancing safety and environmental management, ensuring compliance with regulations, and maintaining a green development approach[107]. Risk Management - The company does not foresee any significant risks that could materially affect its operations during the reporting period[7]. - The company faces risks related to industry policy changes, rising raw material and labor costs, and potential price reductions in drug procurement[112]. - The company has established a comprehensive quality management system to control production processes and mitigate risks associated with product quality issues[113].